Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.73 |
| ▸ | RET | P07949 | 4/20 | 0.72 |
| ▸ | KDR | P35968 | 4/20 | 0.72 |
| ▸ | KIF5B | P33176 | 3/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.61 |
| ▸ | FLT1 | P17948 | 1/20 | 0.61 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.61 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29781309 | 1.00 | EGFR (0.73) | EGFRRETKDRKIF5BKCNH2 | |
| Methane SCHEMBL5123634 | 0.99 | EGFR (0.72) | EGFRRETKDRKIF5BKCNH2 | |
| SCHEMBL2456254 | 0.96 | RET (0.72) | EGFRRETKDRKIF5BERBB2 | |
| SCHEMBL10100955 | 0.91 | KDR (0.75) | EGFRRETKDRKIF5BKCNH2 | |
| Hydrochloric Acid SCHEMBL4558015 | 0.90 | EGFR (0.67) | EGFRRETKDRKIF5BERBB2 | |
| SCHEMBL3690394 | 0.88 | EGFR (0.58) | EGFRRETKDRKIF5BKCNH2 | |
| SCHEMBL16016709 | 0.88 | EGFR (0.67) | EGFRRETKDRKIF5BKCNH2 | |
| SCHEMBL13604777 | 0.87 | EGFR (0.69) | EGFRRETKDRKIF5BKCNH2 | |
| SCHEMBL14843536 | 0.87 | EGFR (0.70) | EGFRRETKDRKIF5BKCNH2 | |
| SCHEMBL21541701 | 0.87 | EGFR (0.66) | EGFRRETKDRKIF5BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487806-B1 | 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | ASTRAZENECA AB (SE) | 2010-07-07 | — | — | EP | claimed |
| EP-4446324-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2024-10-16 | — | — | EP | disclosed |
| WO-2024059668-A2 | HYDROXYLAMINE-BASED EGFR INHIBITORS FOR TREATMENT OF CANCER WITH BRAIN METASTASES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| CN-116239566-A | E3 ubiquitin ligase ligand compound, protein degradation agent developed based on ligand compound and application thereof | 标新生物医药科技(上海)有限公司 | 2023-06-09 | — | — | CN | disclosed |
| EP-3733663-B1 | 1-[6-[[4-(PHENYLAMINO)-6-QUINAZOLINYL]OXY]-3-AZABICYCLO[3.1.1]HEPT-3-YL]-2-PROPEN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS IRREVERSIBLE INHIBITORS OF PAN-HER TYROSINE KINASE FOR THE TREATMENT OF CANCER | CHENGDU JINRUI FOUND BIOTECH CO LTD (CN) | 2023-05-17 | — | — | EP | disclosed |
| CN-113307797-B | Polysubstituted quinazoline compound and application thereof | 江南大学 | 2022-08-09 | — | — | CN | disclosed |
| US-11377451-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-05 | — | — | US | disclosed |
| EP-3342770-B1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | ASTRAZENECA AB (SE) | 2022-03-30 | — | — | EP | disclosed |
| US-20220064177-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-03 | — | — | US | disclosed |
| EP-1664030-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| EP-1660479-A1 | PIPERIDYL-QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | Astrazeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| US-20050215574-A1 | 4-anilino quinazoline derivatives as antiproliferative agents | ASTRAZENECA AB (SE) | 2005-09-29 | — | — | US | disclosed |
| WO-2005075439-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
| US-20050165035-A1 | Quinazoline derivatives | ASTRAZENECA AB | 2005-07-28 | — | — | US | disclosed |
| WO-2005026150-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
| WO-2005026156-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
| WO-2005012290-A1 | PIPERIDYL-QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-02-10 | — | — | WO | disclosed |
| EP-1487806-A1 | 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | Astrazeneca AB (SE) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003082831-A1 | 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215574-A1 | 4-anilino quinazoline derivatives as antiproliferative agents | ERBB2, ERBB4, EGFR | EGFR 3/4885RET 49/4885KDR 70/4885 |
| US-11377451-B2 | Compositions and methods for treating cancer | TP53, EGFR, SLC2A1 | EGFR 2/4885RET 214/4885KDR 210/4885 |
| US-20050165035-A1 | Quinazoline derivatives | ERBB2, EGFR, ERBB4 | EGFR 2/4885RET 13/4885KDR 16/4885 |
| US-20220064177-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, SLC2A1, EGFR | EGFR 3/4885RET 262/4885KDR 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.